MCID: TCK001
MIFTS: 55

Tick-Borne Encephalitis

Categories: Rare diseases, Neuronal diseases, Infectious diseases

Aliases & Classifications for Tick-Borne Encephalitis

MalaCards integrated aliases for Tick-Borne Encephalitis:

Name: Tick-Borne Encephalitis 12 72 49 55 14 69
Siberian Tick-Borne Encephalitis 12 69
Western European Tick-Borne Encephalitis 12
Russian Spring-Summer Encephalitis 12
Encephalitis, Far Eastern Russian 69
Encephalitis, Central European 69
Central European Encephalitis 12
West-Siberian Encephalitis 12
Encephalitis, Tick-Borne 41
Encephalitis Tick-Borne 51
Taiga Encephalitis 12
Far Eastern Tbe 12
Tbe 55

Characteristics:

Orphanet epidemiological data:

55
tick-borne encephalitis
Inheritance: Not applicable; Age of onset: All ages; Age of death: any age;

Classifications:



External Ids:

Disease Ontology 12 DOID:0050175
ICD10 32 A84.1
ICD9CM 34 063.2
MeSH 41 D004675
SNOMED-CT 64 16901001
Orphanet 55 ORPHA297
MESH via Orphanet 42 D004675
UMLS via Orphanet 70 C0014061
ICD10 via Orphanet 33 A84.0 A84.1 A84.8 more

Summaries for Tick-Borne Encephalitis

Disease Ontology : 12 A viral infectious disease that results_in inflammation located in brain, has material basis in Tick-borne encephalitis virus, which is transmitted_by Ixodes ticks. The infection has symptom drowsiness, has symptom confusion, has symptom sensory disturbances, and has symptom paralysis.

MalaCards based summary : Tick-Borne Encephalitis, also known as siberian tick-borne encephalitis, is related to encephalitis and hemorrhagic fever, and has symptoms including drowsiness, confusion and sensory disturbances. An important gene associated with Tick-Borne Encephalitis is SCRIB (Scribbled Planar Cell Polarity Protein), and among its related pathways/superpathways are Innate Immune System and Cytokine Signaling in Immune system. The drugs Dimenhydrinate and Formaldehyde have been mentioned in the context of this disorder. Affiliated tissues include brain, brain and testes, and related phenotype is neoplasm.

Wikipedia : 72 Tick-borne encephalitis (TBE) is a viral infectious disease involving the central nervous system. The... more...

Related Diseases for Tick-Borne Encephalitis

Diseases related to Tick-Borne Encephalitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 91)
# Related Disease Score Top Affiliating Genes
1 encephalitis 31.1 CCR5 CD209 CXCL10 SCRIB TLR3
2 hemorrhagic fever 30.2 ALB CD209 IL10
3 west nile virus 30.2 CCR5 CD209 OAS1 TLR3
4 japanese encephalitis 30.0 CD209 CXCL10 TLR3
5 multiple sclerosis 28.9 CCR5 CXCL10 CXCL11 IL10
6 powassan encephalitis 11.2
7 cow milk allergy 10.4 CCR5 IL10
8 aging 10.4
9 orofacial granulomatosis 10.4 CCR5 IL10
10 human granulocytic anaplasmosis 10.3
11 ehrlichiosis 10.3
12 dengue virus 10.3
13 thrombocytopenia 10.3
14 dermal ridges-off-the-end 10.2
15 noonan syndrome 5 10.2
16 louping ill 10.2
17 tick infestation 10.2
18 neuronitis 10.2
19 venezuelan equine encephalitis 10.2
20 west nile encephalitis 10.2 OAS1 OAS3
21 chronic graft versus host disease 10.2 ALB IL10
22 mucocutaneous leishmaniasis 10.2 CCR5 IL10 TLR3
23 fascioliasis 10.2 ALB IL10
24 hand, foot and mouth disease 10.2 IL10 OAS1
25 lipoid nephrosis 10.1 ALB IL10
26 noonan syndrome 3 10.1
27 meningoencephalitis 10.1
28 kyasanur forest disease 10.1
29 lyme disease 10.1
30 crimean-congo hemorrhagic fever 10.1
31 vaccinia 10.1
32 herpes simplex 10.1
33 meningitis 10.1
34 transmitted_by 10.1
35 herpes simplex encephalitis 10.1
36 hepatitis e 10.1 ALB TLR3
37 extrinsic cardiomyopathy 10.1 IL10 TLR3
38 microphthalmia with limb anomalies 10.1 OAS1 OAS3
39 yellow fever 10.1 CCR5 OAS1
40 polyradiculoneuropathy 10.1 ALB IL10
41 acquired immunodeficiency syndrome 10.0 ALB CCR5 IL10
42 hemorrhagic fever with renal syndrome 10.0 ALB IL10
43 blood group, i system 10.0
44 myositis 10.0
45 chorea, childhood-onset, with psychomotor retardation 10.0
46 multiple mitochondrial dysfunctions syndrome 5 10.0
47 dengue disease 10.0
48 hepatitis 10.0
49 hepatitis b 10.0
50 zika fever 10.0

Graphical network of the top 20 diseases related to Tick-Borne Encephalitis:



Diseases related to Tick-Borne Encephalitis

Symptoms & Phenotypes for Tick-Borne Encephalitis

Symptoms:

12
  • drowsiness
  • confusion
  • sensory disturbances
  • paralysis

MGI Mouse Phenotypes related to Tick-Borne Encephalitis:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 neoplasm MP:0002006 9.02 ALB CCR5 IL10 SCRIB TLR3

Drugs & Therapeutics for Tick-Borne Encephalitis

Drugs for Tick-Borne Encephalitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 32)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dimenhydrinate Approved Phase 4 523-87-5 441281
2
Formaldehyde Approved, Vet_approved Phase 4 50-00-0 712
3 Vaccines Phase 4,Phase 2,Phase 3,Phase 1
4 Antibodies Phase 4
5 Immunoglobulins Phase 4
6 Pharmaceutical Solutions Phase 4
7 Anti-Infective Agents Phase 4
8 Disinfectants Phase 4
9 Blood Substitutes Phase 4
10 Plasma Substitutes Phase 4
11 Polygeline Phase 4
12
Lactitol Investigational Phase 3 585-86-4 3871
13
Doxycycline Approved, Investigational, Vet_approved 564-25-0 54671203
14
Granisetron Approved, Investigational 109889-09-0 3510
15
Ceftriaxone Approved 73384-59-5 5479530 5361919
16
Dopamine Approved 51-61-6, 62-31-7 681
17 Anti-Bacterial Agents
18 Antibiotics, Antitubercular
19 Antiemetics
20 Antimalarials
21 Antiparasitic Agents
22 Antiprotozoal Agents
23 Antipyretics
24 dipyrone
25 Acyclovir
26 Antiviral Agents
27 Autonomic Agents
28 Dopamine Agents
29 Dopamine Antagonists
30 Gastrointestinal Agents
31 Neurotransmitter Agents
32 Peripheral Nervous System Agents

Interventional clinical trials:

(show all 37)

# Name Status NCT ID Phase Drugs
1 TBE Vaccination in Allergic Patients Unknown status NCT02511535 Phase 4
2 Study to Evaluate Long Term Immunogenicity up to 10 Years After the First Booster Immunization With Tick Borne Encephalitis Vaccine in Adults Who Received 1 of 3 Different Primary Vaccination Schedules Completed NCT01562444 Phase 4
3 An Extension Study to Determine the Persistence of Tick-borne Encephalitis (TBE)-Specific Antibody Responses Among Children and Adolescents Previously Immunized Against TBE Completed NCT01106482 Phase 4
4 Cervicovaginal Immune Responses to 3 Deltoid or Thigh Intramuscular (IM) TicoVac Completed NCT01710189 Phase 4 TicoVac
5 TBE Antibody Persistence and Booster Vaccination Study in Children and Adolescents (Follow-up to Study 209) Completed NCT00161967 Phase 4
6 Humoral and Cellular Immunity of Low and High-responders After Tick-borne Encephalitis Vaccination Completed NCT00804219 Phase 4
7 TBE Seropersistence up to 10 Years After First Booster in Adults Completed NCT01582698 Phase 4
8 Tick-Borne Encephalitis (TBE) Seropersistence After First Booster in Children, Adolescents and Young Adults (Follow-Up to Study 700401) Completed NCT00894686 Phase 4
9 TBE Antibody Persistence and Booster Vaccination Study in Adults (Follow-up to Study 223) Completed NCT00503529 Phase 4
10 Immunogenicity and Safety Study of a Rapid Immunization Schedule With FSME-IMMUN 0.5 mL in Healthy Adults Aged 16 - 65 Years Completed NCT00161954 Phase 4
11 Influence of Persistent CMV-infection on Immune Senescence Completed NCT00461695 Phase 4
12 Investigation of the Seropersistence of TBE Antibodies and the Booster Response to FSME-IMMUN 0.5 ml in Adults Aged 18 - 67 Years Completed NCT00161785 Phase 4
13 Evaluation of Long-Term Immunogenicity in Subjects Boosted With a TBE Vaccine for Adults Completed NCT00311493 Phase 4
14 Study of the Safety, Tolerability and Immune Response of TBE Vaccines Administered to Healthy Children Completed NCT00311441 Phase 4
15 Study to Investigate the Seropersistence of TBE Virus Antibodies Approx. 3 Years After a Booster Vaccination With FSME-IMMUN 0.25 mL JUNIOR in Children Completed NCT00163618 Phase 4
16 Immunogenicity and Safety Study of a Third Vaccination With FSME-IMMUN 0.5 mL in Subjects Previously Vaccinated According to a Rapid Immunization Schedule (Follow-up to Study 225) Completed NCT00163540 Phase 4
17 The Aim of This Study is to Investigate the Persistence of Antibody Response in Adults up to 15 Years After One Booster Dose of GlaxoSmithKline (GSK) Biologicals' Encepur Adults Vaccine Active, not recruiting NCT03294135 Phase 4
18 Humoral Response to Tick-borne Encephalitis Vaccine in Elderly Completed NCT01361776 Phase 2, Phase 3
19 Immunogenicity, Safety and Interchangeability of Two Tbe Vaccines Administered According to a Conventional Schedule in Children Completed NCT00840801 Phase 3
20 FSME IMMUN NEW Follow-up to Study 208 in Volunteers Aged 16 to 66 Years Completed NCT00161876 Phase 3
21 Safety and Immunogenicity Study of 3 Vaccinations With TICOVAC in 2 Dosages in Healthy Children Aged Between 6 Months and 3 Years Completed NCT00161746 Phase 2, Phase 3
22 Safety Study in Volunteers From 16 to 65 Years of Age: FSME IMMUN NEW vs. ENCEPUR Completed NCT00161824 Phase 3
23 Safety Study of FSME-IMMUN NEW in Healthy Children and Adolescents Aged 1 to 15 Years Completed NCT00161863 Phase 3
24 Study to Evaluate the Efficacy, Safety and Immunogenicity of Influenza Vaccine in Healthy Subjects (Aged 6 to <72 Months) Versus Control Vaccines Completed NCT00644059 Phase 3
25 New Study - Humoral Response to Tick-borne Encephalitis Vaccine in Elderly Active, not recruiting NCT02318069 Phase 2, Phase 3
26 Evaluation of Immunogenicity of Different Tick Borne Encephalitis (TBE) Fast Protective Traveler Schemes With Inactivated TBE Whole Virus Vaccine Unknown status NCT00890422 Phase 2
27 Dose-finding Study to Investigate the Safety and Immunogenicity of Two Vaccinations With FSME IMMUN NEW in Healthy Volunteers Aged 6 to 16 Years. Completed NCT00161798 Phase 2
28 Dose-finding Study to Investigate the Safety and Immunogenicity of Two Vaccinations With FSME IMMUN NEW in Healthy Volunteers Aged 1 to 6 Years. Completed NCT00161772 Phase 2
29 FSME IMMUN NEW Follow-up to Study 205 in Children Aged 6 to 16 Years Completed NCT00161889 Phase 2
30 FSME IMMUN NEW Follow-up to Study 199 in Children Aged 1 to 6 Years Completed NCT00161850 Phase 2
31 Humoral and Cellular Immunity for TBE Vaccination in Allogeneic HSCT Recipients Recruiting NCT01991067 Phase 2
32 A Phase II, Open Label Trial of a Vaccine (FSME-IMMUN 0.5 mL) Against Tick-borne Encephalitis (TBE) for NIAID Workers Manipulating Tick Borne Encephalitis Virus (TBEV) in the Laboratory Terminated NCT01031537 Phase 2
33 Safety of and Immune Response to a Tick-Borne Encephalitis Vaccine (LGT(TP21)/DEN4) in Healthy Adults Completed NCT00118924 Phase 1
34 Postencephalitic Symptoms After Tick Borne Encephalitis Unknown status NCT00941590
35 Study to Investigate the Immune Response and Safety of Prophylactic Vaccines in Patients Treated for Multiple Sclerosis Completed NCT02275741
36 Tick-borne Encephalitis and Positive Borrelial Antibodies Recruiting NCT02463942 Doxycycline;Symptomatic therapy
37 Aseptic Meningoencephalitis in Slovenia Recruiting NCT02328469 symptomatic therapy;Ceftriaxone or Doxycycline;Acyclovir

Search NIH Clinical Center for Tick-Borne Encephalitis

Cochrane evidence based reviews: encephalitis, tick-borne

Genetic Tests for Tick-Borne Encephalitis

Anatomical Context for Tick-Borne Encephalitis

The Foundational Model of Anatomy Ontology organs/tissues related to Tick-Borne Encephalitis:

18
Brain

MalaCards organs/tissues related to Tick-Borne Encephalitis:

38
Brain, Testes, T Cells, Neutrophil, Nk Cells, B Cells, Liver

Publications for Tick-Borne Encephalitis

Articles related to Tick-Borne Encephalitis:

(show top 50) (show all 673)
# Title Authors Year
1
Diagnosing tick-borne encephalitis: a re-evaluation of notified cases. ( 29188467 )
2018
2
Tick-Borne Encephalitis Virus Vaccine-Induced Human Antibodies Mediate Negligible Enhancement of Zika Virus Infection<i>In</i><i>Vitro</i>and in a Mouse Model. ( 29435494 )
2018
3
Exposure to West Nile virus and tick-borne encephalitis virus in dogs in Spain. ( 29322674 )
2018
4
First detection of tick-borne encephalitis virus RNA in clinical specimens of acutely ill patients in Hungary. ( 29373305 )
2018
5
Distinction between serological responses following tick-borne encephalitis virus (TBEV) infection vs vaccination, Sweden 2017. ( 29386094 )
2018
6
Meningoencephaloradiculitis following infection with tick borne encephalitis virus: case report and review of the literature. ( 29313244 )
2018
7
The long-term outcome of tick-borne encephalitis in Central Europe. ( 29275872 )
2018
8
Second five-year follow-up after a booster vaccination against tick-borne encephalitis following different primary vaccination schedules demonstrates at least 10a8^years antibody persistence. ( 29397225 )
2018
9
Borrelia burgdorferi sl and tick-borne encephalitis virus coinfection in Eastern France. ( 29449048 )
2018
10
Viperin restricts Zika virus and tick-borne encephalitis virus replication by targeting NS3 for proteasomal degradation. ( 29321318 )
2018
11
Structure of tick-borne encephalitis virus and its neutralization by a monoclonal antibody. ( 29382836 )
2018
12
Brain perfusion alterations in tick-borne encephalitis-preliminary report. ( 29337197 )
2018
13
Analysis of tick-borne encephalitis virus-induced host responses in human cells of neuronal origin and interferon-mediated protection. ( 28786780 )
2017
14
Tick-borne encephalitis virus neutralization by high dose intravenous immunoglobulin. ( 27884572 )
2017
15
Analysis of the relationship between single nucleotide polymorphism of the CD209, IL-10, IL-28 and CCR5 D32 genes with the human predisposition to developing tick-borne encephalitis. ( 28894041 )
2017
16
Partial Characterization of Tick-Borne Encephalitis Virus Isolates from Ticks of Southern Ukraine. ( 28654319 )
2017
17
Adaptation of tick-borne encephalitis virus from human brain to different cell cultures induces multiple genomic substitutions. ( 28631054 )
2017
18
Tick-borne encephalitis in Japan, Republic of Korea and China. ( 28928417 )
2017
19
A comparative analysis on the physicochemical properties of tick-borne encephalitis virus envelope protein residues that affect its antigenic properties. ( 28625666 )
2017
20
Cross-neutralisation of viruses of the tick-borne encephalitis complex following tick-borne encephalitis vaccination and/or infection. ( 29263866 )
2017
21
New genetic lineage within the Siberian subtype of tick-borne encephalitis virus found in Western Siberia, Russia. ( 29069610 )
2017
22
EAN consensus review on prevention, diagnosis and management of tick-borne encephalitis. ( 28762591 )
2017
23
Necessity of a Surveillance System for Tick-borne Encephalitis. ( 28540160 )
2017
24
Deep sequencing analysis of tick-borne encephalitis virus from questing ticks at natural foci reveals similarities between quasispecies pools of the virus. ( 28073402 )
2017
25
Tick-borne encephalitis in a naturally infected sheep. ( 28830430 )
2017
26
COMPARISON BETWEEN PROTON MAGNETIC RESONANCE SPECTROSCOPY FINDINGS IN DOGS WITH TICK-BORNE ENCEPHALITIS AND CLINICALLY NORMAL DOGS. ( 27714889 )
2017
27
Engineering of Chimeric Protein Based on E Protein Domain III of Tick-Borne Encephalitis Virus and OmpF Porin of Yersinia pseudotuberculosis. ( 28741465 )
2017
28
Reconsidering the classification of tick-borne encephalitis virus within the Siberian subtype gives new insights into its evolutionary history. ( 28919548 )
2017
29
Transcriptional Immunoprofiling at the Tick-Virus-Host Interface during Early Stages of Tick-Borne Encephalitis Virus Transmission. ( 29250492 )
2017
30
Predictability of tick-borne encephalitis fluctuations. ( 28791941 )
2017
31
Molecular Detection and Serological Evidence of Tick-Borne Encephalitis Virus in Serbia. ( 29064333 )
2017
32
Report of the 19th Annual Meeting of the International Scientific Working Group on Tick-Borne Encephalitis (ISW-TBE) - TBE in a changing world. ( 28918352 )
2017
33
Cyclic patterns in the central European tick-borne encephalitis incidence series. ( 27772539 )
2017
34
Tick-Borne Encephalitis in Sheep, Romania. ( 29148377 )
2017
35
The increased concentration of macrophage migration inhibitory factor in serum and cerebrospinal fluid of patients with tick-borne encephalitis. ( 28646884 )
2017
36
Goats as sentinel hosts for the detection of tick-borne encephalitis risk areas in the Canton of Valais, Switzerland. ( 28693561 )
2017
37
Human Tick-Borne Encephalitis, the Netherlands. ( 27938522 )
2017
38
Properties of the tick-borne encephalitis virus population during persistent infection of ixodid ticks and tick cell lines. ( 28784308 )
2017
39
Systematic literature review comparing rapid 3-dose administration of the GSK tick-borne encephalitis vaccine with other primary immunization schedules. ( 28770638 )
2017
40
Comparison of six commercial tick-borne encephalitis IgM and IgG ELISA kits and the molecular characterization of their antigenic design. ( 29366629 )
2017
41
Geographical Environment Factors and Risk Assessment of Tick-Borne Encephalitis in Hulunbuir, Northeastern China. ( 28587151 )
2017
42
Serum carnitine and acyl-carnitine in patients with meningitis due to tick-borne encephalitis virus infection. ( 28791846 )
2017
43
Travel-Related Tick-Borne Encephalitis, Israel, 2006-2014. ( 27779467 )
2017
44
A database of human genes and a gene network involved in response to tick-borne encephalitis virus infection. ( 29297316 )
2017
45
Comparative analysis of genomes of tick-borne encephalitis virus strains isolated from mosquitoes and ticks. ( 29323844 )
2017
46
Morphological anomalies in Ixodes ricinus and Ixodes inopinatus collected from tick-borne encephalitis natural foci in Central Europe. ( 28755284 )
2017
47
Epidemiology of tick-borne encephalitis (TBE) in international travellers to Western/Central Europe and conclusions on vaccination recommendations. ( 27087558 )
2016
48
Influence of climatic, demographic and socioeconomic factors on tick-borne encephalitis incidence in 6 counties of Podlaskie region in 1994-2014. ( 27344469 )
2016
49
Post Tick-Borne Encephalitis Virus Vaccination Narcolepsy with Cataplexy. ( 27397572 )
2016
50
Biomarkers in Cerebrospinal Fluid of Children with Tick-Borne Encephalitis: Association with Long-Term Outcome. ( 27187756 )
2016

Variations for Tick-Borne Encephalitis

Expression for Tick-Borne Encephalitis

Search GEO for disease gene expression data for Tick-Borne Encephalitis.

Pathways for Tick-Borne Encephalitis

Pathways related to Tick-Borne Encephalitis according to GeneCards Suite gene sharing:

(show all 14)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.69 CCR5 CD209 CXCL10 IFNL3 IL10 OAS1
2
Show member pathways
12.91 CCR5 CXCL10 IFNL3 IL10 OAS1 OAS3
3
Show member pathways
12.38 CD209 IFNL3 OAS1 OAS3 TLR3
4 12.18 CXCL10 IL10 OAS1 TLR3
5
Show member pathways
12.05 CXCL10 CXCL11 IL10 TLR3
6
Show member pathways
12.05 CD209 CXCL10 OAS1 OAS3 TLR3
7
Show member pathways
11.82 IL10 OAS1 OAS3
8 11.75 OAS1 OAS3 TLR3
9
Show member pathways
11.64 CCR5 CXCL10 CXCL11
10 11.1 CXCL10 OAS1
11 11.06 CXCL10 CXCL11
12 10.92 CXCL10 CXCL11 IL10
13
Show member pathways
10.84 IFNL3 OAS1
14 10.49 CCR5 CXCL10 IL10

GO Terms for Tick-Borne Encephalitis

Cellular components related to Tick-Borne Encephalitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.43 ALB CXCL10 CXCL11 IFNL3 IL10 OAS3
2 external side of plasma membrane GO:0009897 9.33 CCR5 CD209 CXCL10
3 extracellular region GO:0005576 9.17 ALB CD209 CXCL10 CXCL11 IFNL3 IL10

Biological processes related to Tick-Borne Encephalitis according to GeneCards Suite gene sharing:

(show all 19)
# Name GO ID Score Top Affiliating Genes
1 immune system process GO:0002376 9.86 CD209 OAS1 OAS3 TLR3
2 regulation of receptor activity GO:0010469 9.84 CXCL10 CXCL11 IFNL3 IL10
3 innate immune response GO:0045087 9.8 CD209 IFNL3 OAS1 OAS3 TLR3
4 cell-cell signaling GO:0007267 9.76 CCR5 CXCL10 CXCL11 IL10
5 response to lipopolysaccharide GO:0032496 9.75 CXCL10 CXCL11 IL10
6 chemotaxis GO:0006935 9.72 CCR5 CXCL10 CXCL11
7 inflammatory response GO:0006954 9.72 CCR5 CXCL10 CXCL11 IL10 TLR3
8 cellular response to lipopolysaccharide GO:0071222 9.7 CCR5 CXCL10 IL10
9 chemokine-mediated signaling pathway GO:0070098 9.61 CCR5 CXCL10 CXCL11
10 negative regulation of mitotic cell cycle GO:0045930 9.58 IL10 SCRIB
11 positive regulation of release of sequestered calcium ion into cytosol GO:0051281 9.57 CXCL10 CXCL11
12 defense response GO:0006952 9.56 CCR5 CXCL10 CXCL11 TLR3
13 negative regulation of viral genome replication GO:0045071 9.54 IFNL3 OAS1 OAS3
14 positive regulation of cAMP-mediated signaling GO:0043950 9.51 CXCL10 CXCL11
15 positive regulation of cAMP metabolic process GO:0030816 9.49 CXCL10 CXCL11
16 T cell chemotaxis GO:0010818 9.48 CXCL10 CXCL11
17 response to virus GO:0009615 9.46 CXCL10 OAS1 OAS3 TLR3
18 immune response GO:0006955 9.43 CCR5 CXCL10 CXCL11 IL10 OAS1 OAS3
19 defense response to virus GO:0051607 9.02 CXCL10 IFNL3 OAS1 OAS3 TLR3

Molecular functions related to Tick-Borne Encephalitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 double-stranded RNA binding GO:0003725 9.43 OAS1 OAS3 TLR3
2 cytokine activity GO:0005125 9.26 CXCL10 CXCL11 IFNL3 IL10
3 CXCR3 chemokine receptor binding GO:0048248 9.16 CXCL10 CXCL11
4 2-5-oligoadenylate synthetase activity GO:0001730 8.62 OAS1 OAS3

Sources for Tick-Borne Encephalitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....